The efficacy and safety of combination therapy of adoptive immunotherapy with chemotherapy for advanced pancreatic cancer
Not Applicable
- Conditions
- unresectable advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000011177
- Lead Sponsor
- Tokai University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Interstitial pneumonia 2. Active autoimmune disease 3. Uncontroled infection 4. Severe drug allergy 5. Continued steroid therapy 6. Pregnancy 7. HIV or HTLV-1 positive
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method